W.O.M. World of Medicine AG

euro adhoc: W.O.M. World of Medicine AG
Quarterly or Semiannual Financial Statements
Despite earnings improvement, WORLD OF MEDICINE faces continued risks to achieving net profits in 2004

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- Weaker US dollar dampens the strong growth of Minimally Invasive Surgery (MIS®) in the USA/ MIS® - without industrial laser division - reaches operative turnaround after nine months/ WORLD OF MEDICINE, developer of medical device technology for Minimally Invasive Surgery (MIS®), faces risks to achieving its business year objective of overall net profits for 2004, especially due to the sharp rise in the euro to the US dollar. In the first nine months of 2004, WORLD OF MEDICINE achieved a 7% increase in sales (currency-adjusted*: 15%). The EBIT improved by TEUR298 to -TEUR460 (last year: -TEUR758). Consolidated earnings after nine months totaled -TEUR712 (last year: -TEUR1,018). At last year’s exchange rate with the US dollar, WORLD OF MEDICINE would have already reached a turnaround after nine months. In the third quarter, WORLD OF MEDICINE achieved a 44% increase in US dollar-based sales. WORLD OF MEDICINE attained a currency-adjusted* growth in sales of 4% worldwide in the third quarter. Based on the euro, sales declined in the third quarter by 10%. After consolidation in the third quarter, the healthy level of orders should support growth in sales in the fourth quarter of 2004. The successful approval of prototypes for important projects at the IB Laser subsidiary places additional sales and earnings potential in the fourth quarter within reach. Developments in the currency exchange rate will be particularly decisive in being able to offset accumulated consolidated losses after nine months with consolidated earnings from the fourth quarter. The Management Board is expecting the shift to larger purchasing volumes in US dollars to cushion the impact of currency exchange rate fluctuations during the 2005 business year. Moreover, reaching the break-even point in the fourth quarter at IB Laser, the industrial laser division, is a condition to achieving net profits for the year 2004 as a whole. The operative turn-around in MIS® was reached within nine months, with an EBIT of TEUR133 (last year: -TEUR453). Additional opportunities for MIS® in the fourth quarter are expected from the boost in demand after Medica, the most important trade show in the industry, in November, as well as the scheduled delivery of larger orders from Flow&FluidWORLD® and LaserWORLD through the end of the year. The complete 9-Month Report is available for review via the internet at www.world-of-medicine.com. Please find the html-version of the 9-Month Report at: http://irreports.equitystory.com/cgi-bin/show.ssp?fn=show&report_id=womQ304&lang=English The Management Board * Currency adjusted: Based on the US dollar/EUR exchange rate for the same period last year. end of announcement euro adhoc 11.11.2004 07:32:34 --------------------------------------------------------------------- Further inquiry note: Stefanie Gehrke Tel.: +49 (0)30 39981 566 E-Mail: stefanie.gehrke@womcorp.com Branche: Pharmaceuticals ISIN: DE0006637390 WKN: 663739 Index: Prime Standard, CDAX, Prime All Share, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing Berliner Wertpapierbörse / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade Bremer Wertpapierbörse (BWB) / free trade

Das könnte Sie auch interessieren: